Hong Kong Industry Works With Regulator To Ensure Open Market Stays Open
This article was originally published in PharmAsia News
Executive Summary
Major changes are afoot in Hong Kong’s drug approval and regulatory process with safety a prime focus following a series of reforms implemented last year in response to six deaths from spurious generic drugs in 2009.